Stock Ratings | Up to $300! Major banks raise their price target for Nvidia; HC Wainwright lowers its price target for FBLG to $4, with a potential upside of 1313.93%.
NovoCure Ltd. NVCR | 10.55 | -2.68% |
Ironwood Pharmaceuticals, Inc. Class A IRWD | 3.54 | -9.23% |
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | 30.83 | +1.72% |
Dynatrace Holdings DT | 37.69 | +2.50% |
FibroBiologics, Inc. FBLG | 1.38 | +3.76% |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
HC Wainwright & Co.: Maintaining a "buy" rating on NovoCure ( NovoCure Ltd.(NVCR.US) ), with a price target raised from $47 to $49.
Citizens: Maintaining Ironwood Pharmaceuticals' ( Ironwood Pharmaceuticals, Inc. Class A(IRWD.US) ) rating at "Outperform Market", while raising the price target from $8 to $10.
Needham: Maintaining a "buy" rating on Immunocore Holdings ( Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh(IMCR.US) ), while raising the price target from $71 to $75.
Macquarie: Initial rating for Dynatrace ( Dynatrace Holdings(DT.US) ) stock at "neutral", with a target price of $36.
HC Wainwright & Co.: Maintaining a "buy" rating on FibroBiologics ( FibroBiologics, Inc.(FBLG.US) ), while lowering the price target from $5 to $4.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| NovoCure Ltd.(NVCR.US) | to lift | $49.0 | $13.75 | 256.36% | HC Wainwright & Co. |
| Ironwood Pharmaceuticals, Inc. Class A(IRWD.US) | to lift | $10.0 | $3.66 | 173.22% | Citizens |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh(IMCR.US) | to lift | $75.0 | $32.04 | 134.08% | Needham |
| Taboola.com Ltd.(TBLA.US) | to lift | $7.0 | $3.06 | 128.76% | Rosenblatt |
| Xencor, Inc.(XNCR.US) | to lift | $27.0 | $13.55 | 99.26% | Barclays |
| Dynatrace Holdings(DT.US) | Initial classification | $36.0 | $36.35 | -0.96% | Macquarie |
| FibroBiologics, Inc.(FBLG.US) | cut | $4.0 | $0.2829 | 1313.93% | HC Wainwright & Co. |
| Zevia PBC Class A(ZVIA.US) | cut | $5.0 | $1.35 | 270.37% | Telsey Advisory Group |
| Enovix Corporation(ENVX.US) | cut | $15.0 | $5.95 | 152.1% | Canaccord Genuity |
| Pelthos Therapeutics Inc.(PTHS.US) | cut | $55.0 | $23.0 | 139.13% | Roth Capital |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Benchmark: Maintaining a "buy" rating on IMAX Corporation ( IMAX Corporation(IMAX.US) ), with a price target raised from $42 to $44.
Macquarie: Maintaining IMAX Corporation's ( IMAX Corporation(IMAX.US) ) rating at "Outperforming the Market," while raising the price target from $44 to $45.
Wells Fargo: Maintaining an "overweight" rating on Lowe's ( Lowe's Companies, Inc.(LOW.US) ), while raising the price target from $280 to $290.
RBC Capital: Maintaining Lowe's ( Lowe's Companies, Inc.(LOW.US) ) rating at "sector-matched," while raising the price target from $257 to $264.
Truist Securities: Maintaining a "buy" rating on NVIDIA NVIDIA Corporation(NVDA.US) ) stock, while raising the price target from $275 to $283.
JP Morgan: Maintaining NVIDIA's ( NVIDIA Corporation(NVDA.US) rating at "overweight", while raising the price target from $250 to $265.
Morgan Stanley: Maintaining an "overweight" rating on NVIDIA NVIDIA Corporation(NVDA.US) ) stock, while raising the price target from $250 to $260.
RBC Capital: Maintaining its "Outperform Market" rating for NVIDIA NVIDIA Corporation(NVDA.US) ) stock, while raising its price target from $240 to $250.
Bernstein: Maintaining an "outperform" rating for NVIDIA NVIDIA Corporation(NVDA.US) ) stock, while raising the price target from $275 to $300.
Citigroup: Maintaining a "buy" rating on NVIDIA NVIDIA Corporation(NVDA.US) ) stock, while raising the price target from $270 to $300.
Stifel: Maintain Clear Secure ( Clear Secure, Inc. Class A(YOU.US) ) rating at "Hold", while raising the target price from $38 to $51.
First Coverage
Macquarie: Initial rating on Dynatrace ( Dynatrace Holdings(DT.US) ) stock at "neutral", with a price target of $36
Wedbush: Initial rating for Eikon Therapeutics ( Eikon Therapeutics, Inc.(EIKN.US) ) at "Underperforming the Market", with a price target of $7.
reduction
UBS: Maintaining a "neutral" rating on C3.ai ( C3.ai Inc(AI.US) ), while lowering its price target from $14.5 to $9.
Wedbush: Maintaining C3.ai's ( C3.ai Inc(AI.US) ) rating at "Outperforming the Market," while lowering the price target from $20 to $15.
Needham: Maintain Circle Internet Group's ( Circle(CRCL.US) ) rating at "Buy", while lowering the target price from $190 to $130.
BMO Capital: Maintaining its "Outperform" rating on Salesforce Salesforce.com, inc.(CRM.US) ) stock, while lowering its price target from $235 to $225.
TD Cowen: Maintaining a "buy" rating on Salesforce ( Salesforce.com, inc.(CRM.US) ), while lowering the price target from $325 to $250.
Deutsche Bank: Downgraded First Solar First Solar, Inc.(FSLR.US) ) stock rating to "hold", with a price target cut from $300 to $245.
JP Morgan: Maintaining a "neutral" rating on IonQ ( IonQ, Inc.(IONQ.US) ), while lowering its price target from $47 to $42.
Needham: Maintaining a "buy" rating on IonQ stock ( IonQ, Inc.(IONQ.US) ), while lowering the price target from $80 to $65.
Piper Sandler: Maintaining Snowflake(SNOW.US) 's rating at "overweight", while lowering the price target from $285 to $230.
Macquarie: Maintaining Snowflake's rating at " Snowflake(SNOW.US) ", while lowering the price target from $250 to $177.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.